Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Donostia / San Sebastian – page 11

210 clinical trials in Donostia / San Sebastian, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Donostia / San Sebastian at a glance
210
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

210 trials in Donostia / San Sebastian

Open in trial search

Transitional cell carcinoma

Not recruiting

Study on the Effects of 3 vs 6 Cycles of Platinum-based Chemotherapy and Avelumab in Patients with Advanced Urothelial Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Queen Mary University Of London

Hormone receptor positive breast cancer

Not recruiting

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Parkinson's disease

Not recruiting

Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Fallopian tube cancer+2

Not recruiting

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Relacorilant
  • Sponsor:Corcept Therapeutics Inc.

Facioscapulohumeral muscular dystrophy

Not recruiting

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Losmapimod
  • Sponsor:Fulcrum Therapeutics Inc.

Myotonic dystrophy

Not recruiting

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Graft versus host disease+1

Not recruiting

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Bicycletx Limited

Triple negative breast cancer+1

Not recruiting

Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eribulin
  • Sponsor:Medica Scientia Innovation Research S.L.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Donostia / San Sebastian

What the registry says about research in the country

01 Neurodegenerative Diseases

Groundbreaking research focusing on Parkinson's disease and Alzheimer's disease, including studies of novel therapeutics and disease-modifying treatments.

  • LRRK2-driven Parkinson's treatment evaluation
  • Early-stage Alzheimer's interventions
  • Down syndrome-associated Alzheimer's research

Multiple trials investigating innovative approaches to manage disease progression and symptoms.

02 Oncology Studies

Comprehensive research into various cancer types, with emphasis on advanced colorectal cancer and melanoma treatments.

  • Targeted therapies for pancreatic adenocarcinoma
  • Brain metastases in melanoma patients
  • Innovative combinations for lymphomas

Focus on personalized treatment approaches and novel drug combinations.

03 Rare Diseases

Specialized research targeting Amyotrophic Lateral Sclerosis (ALS) and other rare conditions, exploring innovative therapeutic approaches.

  • Combined therapy approaches for ALS
  • Soft tissue sarcoma treatments
  • Ocular Myasthenia Gravis studies

Development of targeted therapies for challenging medical conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.